Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (MALS verified)

产品评论
货号-规格
价格
Qty.
DM1-Y73-100ug
¥3675.00
DM1-Y73-1mg
¥24255.00
Fiber-add-1piece
可选服务
询价
合计0件 产品金额¥ 0

产品信息

抗体来源(Source)

Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 is a Mouse monoclonal antibody produced from a hybridoma created by fusing SP2/0 myeloma and Mouse B-lymphocytes.

种属(Species)

Mouse

亚型(Isotype)

Mouse IgG1 | Mouse Kappa

偶联(Conjugate)

Unconjugated

抗体类型(Antibody Type)

Hybridoma Monoclonal

种属反应性(Reactivity)

Chemical

免疫原(Immunogen)

DM-1.

特异性(Specificity)

This product is a specific antibody specifically reacts with DM-1&DM-4.

应用(Application)

ApplicationRecommended Usage
ELISA0.4-200 ng/mL

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

纯化(Purification)

Protein A purified / Protein G purified

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.
 

交叉验证(Cross Verification)

This product No cross-reactivity in ELISA with
Trastuzumab Deruxtecan. Sacituzumab Govitecam. Disitamab Vedotin (RC48).

产品数据图

 
 

电泳(SDS-PAGE)

DM-1 SDS-PAGE

Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

DM-1 SEC-MALS

The purity of Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) is more than 90% and the molecular weight of this protein is around 130-160 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-ELISA

DM-1 ELISA

Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 2 μg/mL, add increasing concentrations of Trastuzumab-DM1 (T-DM1), and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 8 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 0.5 ng/mL (QC tested).

Protocol

DM-1 ELISA

Immobilized ADC-DM4 at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) with a linear range of 0.20-6.25ng/mL (Routinely tested).

Protocol

DM-1 ELISA

Immobilized Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73) at 5 μg/mL, add Trastuzumab-DM1 in the 50% Human serum and then add Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 0.5 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) (Routinely tested).

Protocol

DM-1 ELISA

Serial dilutions of DM1 were added into Monoclonal Anti-DM-1&DM-4 Antibody, Mouse IgG1 (Cat. No. DM1-Y73): Trastuzumab-DM1 binding reactions. The half maximal inhibitory concentration (IC50) is 0.148 μg/mL (Routinely tested).

Protocol

 

产品评论
发表评论

背景

Mertansine (DM-1) is a tubulin inhibitor that binds to the ends of microtubules and inhibits microtubule dynamics. DM-1(Mertansine) has antitumor activity and functions as a regulator of tubulin. It is an alpha-amino acid ester, a carbamate, an epoxide, an organic heterocyclic tetracyclic compound, an organochlorine compound, a mercaptan, and a maydenin alkaloid. DM-1, derived from Mydenin, is a cytotoxic component of antibody-drug conjugations that produce antibody-drug conjugations via a sulfhydryl group splice with SPP (n-succinimide 4- (2-pyridyl dithio)) or SMCC (4- (3-mercapto-2, 5-dioxy-1 pyrrolidyl) -cyclohexanic acid) splice.

前沿进展

 
靶点信息
  • 英文全称:

    Myotonin-protein kinase

  • 中文全称:

    肌强直蛋白蛋白激酶

  • 种类:

  • 上市药物数量:

    0 详情

  • 临床药物数量:

    2 详情

  • 最高研发阶段:

    临床二期

数据表和文档
联系我们
项目合作
查看更多项目
  • 产品SKU
  • 产品信息
  • 产品数据图
  • 产品评论
  • 背景